Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1 by Nathaniel Weygant et al.
Weygant et al. Molecular Cancer 2014, 13:103
http://www.molecular-cancer.com/content/13/1/103RESEARCH Open AccessSmall molecule kinase inhibitor LRRK2-IN-1
demonstrates potent activity against colorectal
and pancreatic cancer through inhibition of
doublecortin-like kinase 1
Nathaniel Weygant1†, Dongfeng Qu1,2†, William L Berry3,4, Randal May1,2, Parthasarathy Chandrakesan1,
Daniel B Owen1, Sripathi M Sureban1,2, Naushad Ali1,2,3, Ralf Janknecht3,4 and Courtney W Houchen1,2,3,5*Abstract
Background: Doublecortin-like kinase 1 (DCLK1) is emerging as a tumor specific stem cell marker in colorectal and
pancreatic cancer. Previous in vitro and in vivo studies have demonstrated the therapeutic effects of inhibiting
DCLK1 with small interfering RNA (siRNA) as well as genetically targeting the DCLK1+ cell for deletion. However, the
effects of inhibiting DCLK1 kinase activity have not been studied directly. Therefore, we assessed the effects of
inhibiting DCLK1 kinase activity using the novel small molecule kinase inhibitor, LRRK2-IN-1, which demonstrates
significant affinity for DCLK1.
Results: Here we report that LRRK2-IN-1 demonstrates potent anti-cancer activity including inhibition of cancer cell
proliferation, migration, and invasion as well as induction of apoptosis and cell cycle arrest. Additionally we found
that it regulates stemness, epithelial-mesenchymal transition, and oncogenic targets on the molecular level.
Moreover, we show that LRRK2-IN-1 suppresses DCLK1 kinase activity and downstream DCLK1 effector c-MYC, and
demonstrate that DCLK1 kinase activity is a significant factor in resistance to LRRK2-IN-1.
Conclusions: Given DCLK1’s tumor stem cell marker status, a strong understanding of its biological role and
interactions in gastrointestinal tumors may lead to discoveries that improve patient outcomes. The results of this
study suggest that small molecule inhibitors of DCLK1 kinase should be further investigated as they may hold
promise as anti-tumor stem cell drugs.
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Small-molecule kinase inhibitors hold significant promise
in extending lifespan and improving outcomes for cancer
patients. Imatinib (Gleevec®), an inhibitor designed to tar-
get the BCR-ABL fusion complex in chronic myelogenous
leukemia (CML), was the first successful drug in this cat-
egory and exemplifies the therapeutic potential of these
drugs. With this therapy CML has been transformed from
an often-fatal malignancy to a manageable condition with* Correspondence: courtney-houchen@ouhsc.edu
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unless otherwise stated.survival rates similar to the disease-free population [1]. In
solid tumor cancers, many kinase inhibitors such as soraf-
enib and gefitinib have been shown to extend the overall
and progression-free survival of patients [2,3]. However,
only a very small portion of the human kinome has been
targeted with inhibitors at the phase I clinical trial level
[4] and although many kinase inhibitors are currently in
various phases of clinical trials for different cancers, there
is a need for new inhibitors targeting novel kinases impli-
cated in tumorigenesis, recurrence, and metastasis.
Doublecortin-like kinase 1 (DCLK1) is a microtubule-
binding member of the calmodulin-dependent kinaseal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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stem-like properties in the small intestine and pancreas
[5-10]. DCLK1 is overexpressed in tumors and pancre-
atic intraepithelial (PanIN) lesions of P48CreKrasLSLG12D,
Pdx1Cre; KrasLSLG12D, Pdx1Cre; KrasLSLG12D; Tp53Flox/+
and Mist1CreER; KrasLSLG12D pancreatic cancer mice as
well as surgical resection specimens of human pancre-
atic ductal adenocarcinoma (PDAC) patients, and is sig-
nificantly correlated to PanIN lesion stage [8,9]. DCLK1
is also overexpressed in the Apcmin/+ mouse model of in-
testinal neoplasia and surgical specimens of human
colon cancer [5,7]. Recently, cutting-edge studies using
the Dclk1CreERT2; Apcmin/+ lineage tracing mouse model
have demonstrated that Dclk1+ cells selectively mark
tumor stem cells (TSCs) in intestinal adenomas and
diphtheria-toxin inducible ablation of these cells results
in massive loss of polyps with no apparent negative effects
on the normal intestine [11]. Moreover, a recent study
demonstrated that a unique population of DCLK1+ stem-
like cells is capable of initiating pancreatic tumorigenesis
[9]. These data provide a basis for DCLK1 targeted
therapies.
DCLK1 has been targeted on the genetic level in some
cancers with promising results. siRNA-mediated silencing
of DCLK1 triggers apoptosis in SHSY5Y neuroblastoma
cells [12]. Moreover, a recent study demonstrated that
doxycycline-inducible knockdown of DCLK1 inhibits pro-
liferation, mitochondrial activity, and ATP synthesis in
N1E-115 neuroblastoma cells and delays progression of
N1E-115 tumor xenografts [13]. Therapeutic targeting
of DCLK1 in gastrointestinal cancer is highly desirable
because of its expansion in tumors and tumor stem cell
status. siRNA-mediated knockdown of DCLK1 in the
AsPC-1 pancreatic cancer cell line results in inhibition
of epithelial-to-mesenchymal transition (EMT) and
oncogenic targets through induction of tumor suppres-
sor miRNAs let-7a and miR-144 and EMT-inhibitor
miR-200a [8]. In HCT116 (colon) and AsPC-1 (pancre-
atic) tumor xenografts, DCLK1 siRNA nanoparticle
treatment significantly reduces tumor growth and in-
hibits pluripotency and angiogenic factors without any
indication of toxicity [14,15]. Despite these compelling
findings, the effect of inhibiting DCLK1 kinase activity
has not been investigated in cancer. Recently, the Gray
group developed a kinase inhibitor targeting Leucine-
rich repeat kinase 2 (LRRK2), which is implicated in
both genetically predisposed and sporadic Parkinson’s
disease [16]. This compound, LRRK2-IN-1, displayed
significant and relatively selective affinity for DCLK1
(Kd = 5 nM), compared to a Kd of 20 nM for LRRK2
[17]. Here we demonstrate that LRRK2-IN-1 elicits anti-
cancer activity in part through inhibition of DCLK1,
suggesting that DCLK1 kinase may be a promising anti-
cancer target.Results
LRRK2-IN-1 inhibits DCLK1 kinase activity
Kinome profiling suggests that LRRK2-IN-1 (Figure 1A)
inhibits DCLK1 kinase with a dissociation constant of 5
nM [17]. In order to confirm this inhibition we per-
formed an in vitro kinase assay using commercially avail-
able purified DCLK1 protein and autocamtide2 substrate
with low concentration ATP (1 μM). Remaining ATP
following the reaction was quantified using luminescent
kinase-glo® reagents which provides an inverse measure
of kinase activity. Using this assay we estimated the IC50
of LRRK2-IN-1 inhibition of DCLK1 to be 2.61 nM
(Figure 1B), supporting the previously reported kinome
profiling results [17]. To assess the inhibition of DCLK1
phosphorylation in vitro, AsPC-1 cells were treated with
LRRK2-in-1 for 48 h. Phospho-DCLK1 (Ser30/336) was
decreased in both 52 and 82 kDa isoforms (long-β/α
respectively) with LRRK2-IN-1 treatment in a dose-
dependent manner. Quantification of the ratio of phospho-
DCLK1/DCLK1 revealed that the 52 and 82 kDa isoforms
decreased approximately 30% and 12.5% respectively fol-
lowing 5 μM LRRK2-in-1 treatment (p < 0.046; Figure 1C).
LRRK2-IN-1 is an ATP-competitive inhibitor of DCLK1
kinase
Following confirmation of LRRK2-IN-1’s inhibitory ac-
tivity against DCLK1 kinase, in silico molecular model-
ing and docking was conducted to determine the
mechanism and localization of inhibition. Because the
full crystal structure of DCLK1 has not been determined,
homology models were constructed for DCLK1 isoform
2 (DCLK-long-α) and 4 (DCLK-long-β). The protein kin-
ase domain is a highly conserved structural feature of all
kinases and DCLK1 is a member of the calmodulin-
dependent protein kinase (CAMK) family, which has
many structures solved (Additional file 1: Figure S1A).
Therefore, these models are expected to be reasonably
accurate. Both SparksX Fold Recognition and SwissMo-
del generated similar homology models of DCLK1 with
a root mean square deviation (RMSD) of 0.89 Å, while
the RMSD in the kinase domains of the long form
models was 0.37 Å. Docking simulations were conducted
using PatchDock and the homology model of DCLK-
long-β, 81% of which encompasses the protein kinase
domain shared by all DCLK1 isoforms (Figure 1D). In
the kinase domain, the highest ranked docking site for
LRRK2-IN-1 was located directly within the ATP-
binding pocket with close proximity to the kinase hinge
and interacting residues located in the catalytic loop, ac-
tivation loop, glycine-rich loop (P-loop), and αC-helix
and including the highly conserved, catalytic site lysine
112/419 (Figure 1E; Additional file 1: Figure S2A). These
results suggest that LRRK2-IN-1 inhibits DCLK1 kinase
activity by competing with ATP for the binding pocket.
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Figure 1 LRRK2-IN-1 inhibits DCLK1 kinase activity. An in vitro kinase assay was performed using Purified active DCLK1 kinase (0.25 μg) with
2.5 μg of autocamtide II substrate, 1 μM ATP, and either DMSO, 0.6, 2.5, 5, 10, or 50 nM LRRK2-IN-1 (A). Using relative luminescent units (RLU) data,
a sigmoidal-dose response curve was plotted in GraphPad Prism 6.0 (adj. R2 = 0.952) revealing an IC50 value of 2.61 nM (B). AsPC-1 cells were
treated with LRRK2-IN-1 at varying concentrations for 48 h. Following treatment cells were lysed, protein was isolated and quantified by BCA
assay, and immunoblotting was performed with α-phospho-DCLK1. The ratio of phospho-DCLK1 to total DCLK1 (Figure 4B; 48 h) was determined
and demonstrated decreased phosphorylation of DCLK1 (p < 0.05) following treatment (C). Schematic demonstrating the shared protein kinase
domain between DCLK1 isoforms referenced in Uniprot [Swiss-Prot: O15075] (D). Three dimensional view of LRRK2-IN-1 binding site in
DCLK-long-β revealing predicted interactions with residues of the hinge region, catalytic loop (C-loop), activation loop (A-loop), αC-helix (αC), and
the highly conserved lysine (Lys112) of the kinase catalytic domain suggesting that LRRK2-IN-1 competes with ATP for the DCLK1 kinase binding
pocket. Dashed lines mark the hydrogen bond formed with the conserved aspartate (“D” of the “DFG” motif) of the activation loop (E).
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cell death with hallmarks of apoptosis
DCLK1 is overexpressed or demonstrates strong ex-
pression in many colon and pancreatic cancer cell lines
(Additional file 1: Figure S2C) [18,19]. To assess the func-
tional effects of LRRK2-IN-1 in vitro we chose to focus on
the AsPC-1 human pancreatic cancer and HCT116 hu-
man colon cancer cell lines, which are both well charac-
terized for their DCLK1 expression in the literature
[7,9,14,15,20-22]. Both AsPC-1 and HCT116 cells were
treated with various concentrations of LRRK2-IN-1 for
48 h and MTT proliferation assays were conducted. A sig-
nificant dose-dependent reduction of cell proliferationwas observed in the highly proliferative HCT116 colon
cancer cell line (Figure 2A) and the AsPC-1 pancreatic
cancer cell line (Figure 2B). Fitting a sigmoidal-dose re-
sponse curve revealed IC50 values of 1.69 and 1.73 μM for
AsPC-1 (R2 = 0.79) and HCT116 (R2 = 0.94) cell lines re-
spectively. Moreover, this anti-proliferative activity was
observed in DLD-1 and HT-29 colon cancer cells and
MiaPaCa-2 and SW1990 pancreatic cancer cells. Notably,
SW1990 cells, which express high levels of DCLK1
(Additional file 1: Figure S2C), displayed resistance to
LRRK2-IN-1 compared to the other lines with an IC50
of >5 μM (Additional file 1: Figure S1B). Furthermore,
LRRK2-IN-1 was found to have cytotoxic effects in the
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Figure 2 LRRK2-IN-1 elicits anticancer activity in vitro. HCT116 and AsPC-1 cells were seeded into 96-well plates at 104 cells per well and
allowed to attach overnight at 37°C. LRRK2-IN-1 was added in triplicate to the wells at concentrations of 0 (DMSO), 0.3, 0.6, 1.25, 2.5, 5, 10, and
20 μM and incubated at 37°C. After 48 h an MTT proliferation assay was performed and revealed significant inhibition of cell proliferation starting
at 0.62 μM (A-B). A live/dead assay in AsPC-1 cells was performed 24 h post treatment to confirm LRRK2-IN-1’s cytotoxic effect. Additionally, a
luminescent assay revealed that this effect co-ocurred with Caspase 3/7 activation, both p < 0.0001 by ANOVA (C). AsPC-1 cells were seeded into
6-well plates allowed to reach confluence, scratched, and treated with DMSO, 0.5, 5, or 10 μM LRRK2-IN-1 and incubated at 37°C. The wound area
was imaged at baseline, 12, 24, 48, and 72 h and quantified using ImageJ (D-E). mRNA expression analysis of AsPC-1 cells treated with DMSO or
LRRK2-IN-1 at concentrations of 0.5 μM or 5.0 μM for 8 h revealed a significant downregulation (p < 0.01) of apoptosis regulators BCL2, BCL2L1
(BCL-XL), and MCL1 mRNA expression (F). Western blots showed decreased BCL2 and Phosphohistone H3 at both 24 and 48 h post LRRK2-IN-1
treatment (G).
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treatment (Figure 2C; Additional file 1: Figure S2B), and
cells at this time point demonstrated significant dose-
dependent increases in caspase-3/7 activity (Figure 2C),
which was exponentially associated (R2 = 0.98) with loss of
cell viability (Additional file 1: Figure S2D). Moreover,
LRRK2-IN-1 inhibited AsPC-1 migration at 5 and 10 μM
starting after 12 h treatment (Figure 2D-E). Relative to the
original wound area, the average wound area was approxi-
mately 45% 72 h post DMSO treatment, but was approxi-
mately 70% and 80% at this time point for 5 and 10 μM
LRRK2-in-1 treatment respectively. This anti-migratory
effect was highly dose dependent (p < 0.0001 by ANOVA).
Additionally, gene expression levels of apoptosis pathwayinhibitors, BCL2L1 (BCL-XL), BCL2, and MCL1, were sig-
nificantly decreased in AsPC-1 cells treated with LRRK2-
IN-1 for 8 h (Figure 2F). In confirmation of LRRK2-IN-1’s
anti-proliferative and pro-apoptotic properties, mitotic
marker phosphohistone H3 and anti-apoptotic marker
BCL2 protein levels were inhibited 24 and 48 h post treat-
ment in these cells (Figure 2G).
LRRK2-IN-1 induces G1 and G2/M cell cycle arrest
AsPC-1 cells were treated with LRRK2-IN-1 for 24 and
48 h. Cell cycle analyses were performed and revealed
that LRRK2-IN-1 induces G1 arrest at low doses (5 μM)
and G2/M arrest at high doses (20 μM) at both time


















































Figure 3 LRRK2-IN-1 induces G1 and G2 arrest in vitro. Immunofluorescence of AsPC-1 cells treated with LRRK2-IN-1 demonstrating a
decrease in mitotic cells at 48 h as determined by phosphohistone H3 (PHH3) positive cells (A). Cell cycle analysis of AsPC-1 cells 48 h post
LRRK2-IN-1 demonstrating maximum G1 arrest at 5.0 μM and G2/M arrest at 20 μM regardless of ploidy level. Yellow peaks denote aneuploid
populations and arrows identify these populations in the density maps (B). Cell cycle analysis of AsPC-1 cells 24 and 48 h post LRRK2-IN-1 treatment
demonstrating G1 arrest at low doses and potent G2/M arrest at higher doses (C).
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file 1: Figure S2E). Aneuploidy is well known to contribute
to drug resistance [23]. LRRK2-IN-1 also induced G1
and G2/M arrest in aneuploid AsPC-1 cells as demon-
strated by PI analysis (Figure 3B). The dose-dependent
decrease in phosphohistone H3 expression (p = 0.013 by
ANOVA) following treatment suggests arrest of cells in
G2 phase specifically at higher doses (Figures 3A & 2G).
These data demonstrate that LRRK2-IN-1 reduces cancer
cell proliferation and viability by inducing both G1 and G2/
M arrest. Moreover, the divergent cell cycle status following
low and high-dose LRRK2-IN-1 suggests that as drugconcentration increases further inhibition of target kinase
activity, inhibition of a greater number of kinases, or an-
other downstream interaction causes cells to preferentially
pool in G2/M phase.
LRRK2-IN-1 inhibits DCLK1 mRNA and protein expression
Following LRRK2-IN-1 treatment, DCLK1 mRNA levels
were decreased in a time-dependent manner when treated
with 5 μM of LRRK2-IN-1 (p = 0.004 by ANOVA), and in
a dose-dependent manner when treated with various con-
centrations of LRRK2-IN-1 for 8 h (p < 0.0001 by ANOVA;


































































































































































































































































































Figure 4 LRRK2-IN-1 downregulates DCLK1 expression and downstream target c-Myc. LRRK2-in-1 downregulates DCLK1 mRNA expression
in a dose and time-dependent manner in AsPC-1 cells (A). LRRK2-IN-1 significantly downregulates DCLK1 protein expression at 24 and 48 h and
downregulates protein expression of DCLK1 downstream target c-MYC (B-C). NCBI GEO data demonstrating inhibition of MAPK7/ERK5 with
10 μM U0126 resulting in downregulation of DCLK1 gene expression in SW480 cells (D). Treatment of AsPC-1 cells with 10 μM U0126 downregulates
DCLK1 as well as shared downstream target c-MYC’s mRNA and protein levels. However, whereas combined treatment with this dose of U0126
(10 min pretreatment) and 5 μM LRRK2-IN-1 results in synergistic downregulation of c-MYC, DCLK1 is unaffected or slightly upregulated suggesting
that U0126 and LRRK2-IN-1 may regulate DCLK1 mRNA and protein expression by the same mechanism of action (E-G).
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treatment for 8 h. DCLK1 protein levels were also decreased
in a dose-dependent manner, with an approximately 60% re-
duction for the 82 kDa isoform at 24 h, and a 45% reduction
at 48 h following 5 μM LRRK2-IN-1 treatment (p < 0.03;
Figure 4B-C). Downstream target c-MYC protein expres-
sion was also downregulated 24 h following treatment
(Figure 4B). We hypothesized that DCLK1 mRNA and
protein expression is regulated through the inhibition of
another target of LRRK2-IN-1. The MAPK/ERK signaling
pathway is an important regulator of many cellular func-
tions and modulates a wide range of molecular targets.
MAPK7 (ERK5) is inhibited by LRRK2-IN-1 (Kd = 28 nM)
[17], so we investigated whether this may be a feasible
driver of the observed downregulation of DCLK1 geneand protein expression. U0126 was developed as an in-
hibitor of MEK1/2 but has also been shown to inhibit
MAPK7 [24]. Moreover, it was previously reported that
U0126 suppresses upregulation of DCLK1 in response to
NGF stimulation in PC12 cells [25] and a search of the
NCBI gene expression omnibus database produced mul-
tiple datasets demonstrating significant DCLK1 down-
regulation following U0126 inhibition in colon cancer
cell lines (Figure 4D & Additional file 1: Figure S2F)
[26,27]. As predicted, DCLK1 mRNA levels were de-
creased after 10 μM U0126 treatment (Figure 4E). Ten
minutes pretreatment of cells with this dose of U0126
followed by 5 μM LRRK2-IN-1 treatment caused no fur-
ther decrease in DCLK1 gene expression (Figure 4E).
However, MYC, which is downstream of both DCLK1
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synergistically downregulated with combinatorial drug
treatment compared to LRRK2-IN-1 or U0126 treat-
ment alone (p < 0.005; Figure 4E). Highly similar results
were also observed for protein expression of both
DCLK1 and c-MYC 24 h post treatment (p < 0.05;
Figure 4F-G). These results suggest that MAPK7 inhibition
is a likely mechanism of action for DCLK1 downregulation
by LRRK2-IN-1. Moreover, this data suggests that DCLK1
and the MEK1/2-MAPK7 cascade regulate c-MYC expres-
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Figure 5 LRRK2-IN-1 induces anti-oncogenic molecular changes and L
AsPC-1 cells treated with LRRK2-IN-1 show decreased expression of stem (A),
0.5 μM = gray; 5.0 μM = striped bars. p < 0.05). Consistent with the change
decreases invasion in AsPC-1 cells at 5 μM (D). DCLK1 isoform 1 is the mo
Lentiviral overexpression of this isoform and its kinase dead form demons
by real-time RT-PCR of infected HCT116 cells (E – bottom panel). HCT116(v
with LRRK2-IN-1 at various concentrations. After 48 h an MTT proliferation
DCLK1-KD cells demonstrated no change from 0.63 – 2.5 μM and decreas
significantly increased resistance to LRRK2-IN-1 cytotoxicity at 0.63 and 1.2
doses (F). AsPC-1(vector), AsPC-1-DCLK1, and AsPC-1-DCLK1-KD cells were
colonies for 9 days. Colonies were stained with crystal violet and plates w
significant resistance at 0.5 μM compared to vector control cells, while As
compared to vector control cells (G).LRRK2-IN-1 reduces pluripotency and stem cell associated
gene expression
Stem and stem-like cells are characterized by the expres-
sion of specific transcription factors termed pluripotency
factors. We have recently demonstrated that knockdown
of DCLK1 decreases expression of these factors through
regulation of miR-145 [15]. Expression levels of LIN28,
NANOG, and SOX2 were significantly reduced after
LRRK2-IN-1 treatment in AsPC-1 cells (Figure 5A). LGR5
and BMI1 are stem-cell markers coexpressed with DCLK1

































































































RRK2-IN-1 induced cell death depends on DCLK1 kinase activity.
oncogenic (B), and EMT-related gene expression (C) (Vehicle =white;
s seen in EMT-related gene expression, LRRK2-IN-1 significantly
st highly expressed referenced variant in colon cancer (E – top panel).
trates approximately equal levels of DCLK1 transcript as determined
ector), HCT116-DCLK1, and HCT116-DCLK1-KD cell lines were treated
assay was performed. Compared to vector control cells, HCT116-
ed resistance at 5 and 10 μM, while HCT116-DCLK1 cells demonstrated
5 μM concentrations leading to a shift in relative cytotoxicity at low
treated with vehicle, 0.5, or 5 μM of LRRK2-IN-1 and allowed to form
ere divided into grids and counted. AsPC-1-DCLK1 cells demonstrated
PC-1-DCLK1-KD cells demonstrated a significant decrease in resistance
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knockout mice [30], and markers of populations of cells
with tumor stem cell activity in intestinal adenomas [31]
and pancreatic adenocarcinoma [32]. Both LGR5 and
BMI1 mRNA expression levels were significantly down-
regulated following LRRK2-IN-1 treatment (Figure 5A).
These results along with the c-MYC expression results
demonstrate that LRRK2-IN-1 possesses anti-stemness
properties.
LRRK2-IN-1 inhibits oncogenic and EMT marker
gene-expression
Mutation of the KRAS oncogene is the primary initiator
of PDAC and exerts its influence through multiple pro-
tumorigenic pathways [33]. These mutations are also
present with high frequency in colorectal cancer and are
correlated with poor overall survival [34]. LRRK2-IN-1
caused a significant downregulation of KRAS expression
in AsPC-1 cells. Additionally, significant decreases were
found in PDAC related genes NOTCH2-4 and REG4
(Figure 5B). However, there was no effect on NOTCH1
expression (data not shown).
At the time of diagnosis most PDAC patients present
with metastatic disease [35]. Metastasis is driven by the
process of EMT under the control of specific transcription
factors, which allow newly transformed cancer cells to
gain a stem-cell like phenotype [36]. LRRK2-IN-1 signifi-
cantly upregulated epithelial marker E-cadherin (CDH1)
while downregulating EMT factors SNAI1 (SNAIL),
ZEB1, ZEB2, and TWIST1 mRNA expression (Figures 4C).
The WNT pathway is heavily involved in regulating EMT
primarily through nuclear β-catenin [37]. LRRK2-IN-1
downregulated the expression of WNT pathway genes
WNT1, one of the upstream signaling proteins of the
pathway, and TCF7L2/TCF4 (Figure 5C), an essential
transcription factor which in complex with β-catenin dir-
ectly regulates ZEB1 expression [38]. Consistent with the
molecular changes seen in EMT related gene and protein
expression there was a dose-dependent decrease in the in-
vasive potential of AsPC-1 cells 24 h post LRRK2-IN-1
treatment, with an approximately 70% reduction in inva-
sive potential following 5 μM treatment (Figure 5D).
DCLK1 promotes resistance to LRRK2-IN-1
Analysis of RNA deep-sequencing data from the cancer
genome atlas colon cancer dataset [39] revealed that
DCLK1 transcript variant 1, which encodes isoform 1
(also known as DCLK-short-α), is the most highly
expressed annotated variant (Figure 5E). To demonstrate
that DCLK1 is a significant factor in LRRK2-IN-1’s anti-
cancer properties, both HCT116 and AsPC-1 cells were
infected with Lentivirus containing the cDNA of DCLK1
isoform 1 or a kinase-dead mutant (K419R) of this iso-
form, which was previously shown to inactivate DCLK1’skinase activity [40-42]. DCLK1 mRNA expression levels
were increased about 500 fold in both wild type DCLK1
and DCLK1-K419R overexpressing cells compared to
vector infected cells (Figure 5E). DCLK1 has recently
been reported to be a significant contributor to prolifera-
tion and mitochondrial activity in neuroblastoma cells
[13]. We found that overexpression of DCLK1 resulted in
significant resistance to LRRK2-IN-1’s anti-proliferative ef-
fect in the highly proliferative HCT116 cell line up to
2.5 μM (p = 0.03), whereas overexpression of DCLK1-
K419R was virtually identical to vector control at these
doses (Figure 5F). To further characterize DCLK1-based
resistance to LRRK2-IN-1 we performed a colony forma-
tion assay using AsPC-1 cells overexpressing DCLK1 and
DCLK1-K419R. We observed a significant increase in col-
onies formed relative to vector control cells in cells over-
expressing DCLK1 at 0.5 μM (p = 0.035), while cells
overexpressing DCLK1-K419R had fewer colonies at this
concentration. 5 μM LRRK2-IN-1 proved to be highly ef-
fective and colonies were virtually non-existent in all cell
lines (Figure 5G). These results demonstrate that DCLK1
kinase activity confers resistance to LRRK2-IN-1.
LRRK2-IN-1 inhibits the growth of pancreatic tumor
xenografts
To assess the effect of LRRK2-IN-1 in vivo, a tumor
xenograft study (n = 4 per group) was conducted. AsPC-
1 tumor xenografts were injected with LRRK2-IN-1.
Peritumoral injection of the drug resulted in a significant
decrease in tumor volume (Figure 6A). There was also a
notable decrease in the excised volume and weight of
tumors from LRRK2-IN-1 treated mice (Figure 6B-D).
Both the mean excised tumor volume and weight de-
creased more than 50% following LRRK2-IN-1 treatment
for 4 weeks. This data demonstrates that LRRK2-IN-1 is
effective in vivo.
Discussion
The functional significance of DCLK1 in cancer has
only been explored recently. Although siRNA-mediated
knockdown of DCLK1 gene expression is antiprolifera-
tive and induces tumor growth arrest [7,11,13-15], the
effect of inhibiting DCLK1 kinase activity in cancer had
not been previously assessed. The findings presented
here have potentially wide-ranging implications in the
development of novel, targeted agents against DCLK1
and provide additional validation for DCLK1 as a thera-
peutic target. It is notable that some novel anti-cancer
kinase inhibitors such as MAPK7 inhibitor XMD8-92,
PLK1-inhibitor BI-2536, and ALK-inhibitor TAE-684
[43] demonstrate affinity for DCLK1 kinase that is com-
parable to their target kinases (http://lincs.hms.harvard.
edu/). This off-target inhibition may play a role in the
therapeutic effects of these drugs. In fact, DCLK1 gene



























































































Figure 6 LRRK2-IN-1 is effective in vivo. AsPC-1 cells (0.5×106) were injected subcutaneously into the flanks of athymic nude mice (n = 4) and
allowed to grow until the tumor reached an average volume of 100 mm3. LRRK2-IN-1 was solubilized in 20% Captisol® and xenografts were
injected peritumorally with either 20% Captisol (vehicle) or LRRK2-IN-1 (100 mg/kg) for a total of 12 injections. LRRK2-IN-1 treatment resulted in a
significant decrease in tumor volume as a function of time (A) and reduced final excised tumor volume (p = 0.09; B-C) and tumor weight
(p = 0.14; D). The + symbol denotes the mean.
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cell clones that demonstrated resistance to BI-2536 [44].
The structural similarities between these inhibitors and
others that have been synthesized and profiled may aid
in the design of DCLK1 inhibitors with improved chem-
ical characteristics and favorable delivery and safety pro-
files. Additionally, the results of our study suggest the
possibility that DCLK1 kinase activity may be involved
in regulating proliferation, cell cycle, EMT, and stemness
pathways in cancer. However, before these hypotheses
can be confirmed, it will be essential to carefully dissect
the role of each domain in each of the 4 primary human
DCLK1 isoforms in addition to the smaller peptide-like
isoform of DCLK1 (CAMK-related peptide; “CARP”).
The MAPK/ERK pathway regulates many functions es-
sential to cancer cell survival and proliferation [45]. Inthese studies we used U0126 to demonstrate a link be-
tween MEK1/2 cascade inhibition and DCLK1 expression
in human pancreatic cancer cells and confirmed our re-
sults with microarray data generated by other groups in
treated colon cancer cell lines (Figure 4D & Additional file 1:
Figure S2F). Additionally, a previous paper demonstrated
that nuclear translocation of phosphorylated DCLK1-short is
attenuated in U0126-treated Xaenopus laevis melanotrope
cells [46], which if broadly applicable, implies that MEK1/
2 cascade inhibition has the potential to limit or pre-
vent DCLK1-based intracellular signaling. The data from
this study and our previous studies [7,8] suggest that
DCLK1 interacts with and regulates the MAPK/ERK ef-
fector c-MYC. Interestingly, a large-scale protein-protein
interaction study identified physical interaction between
DCLK1 and c-MYC at DCLK1 amino acids 385–399 [47],
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If confirmed, this would suggest that targeting DCLK1
regulates MYC through post-translational modification,
which could also explain the synergistic effect of combina-
torial LRRK2-IN-1 and U0126 treatment on this target.Conclusions
Although the overall function of DCLK1 and it’s multiple
isoforms and functional domains remains to be elucidated,
our studies and others have implicated this protein as a
key regulator of gut injury response and as a major regula-
tor of proliferative, angiogenic, stemness, and EMT path-
ways in cancer. Taken together these findings support
DCLK1’s role as a broad regulator of the molecular and
cellular mechanisms of tumorigenesis. Moreover, the re-
stricted expression of DCLK1 in a limited set of normal
cells and its upregulation and tumor-stem cell status in
cancer tissue make it an ideal target for cancer therapy.
The specificity of LRRK2-IN-1 for DCLK1 and the results
of our studies support the development of DCLK1 kinase
inhibitors against cancer. Given the recalcitrance of ad-
vanced gastrointestinal cancers in general, this therapeutic
concept may have the potential to overcome limitations of
current therapies which only target proliferating cells in
the primary tumor, by repressing the EMT processes and
stemness characteristics that fuel the fatal metastatic and
drug resistant characteristics of advanced tumors.Methods
In vitro kinase assay
Purified kinase-active DCLK1 (0.25 μg, Signalchem) was
incubated in kinase buffer II (Alfa Aesar) with 2.5 μg of
autocamtide II substrate (American Peptide Co.), 1 μM
ATP (Sigma), and either DMSO, 0.6, 1.25, 2.5, 5, 10, or
50 nM LRRK2-IN-1 (Calbiochem) for 15 min at 30°C.
Subsequently, Kinase-Glo® reagent (Promega) was added
1:1 to the reactions which were gently mixed and then
incubated for another 15 minutes protected from light.
Results were obtained using a Synergy HT plate reader
(Biotek) capable of luminometric measurements.Molecular docking analysis
The ligand structure for LRRK2-IN-1 was constructed in
ChemDraw (CambridgeSoft®) and energy-minimized with
UCSF Chimera [48]. Homology models of DCLK1 isoform
2 (DCLK-long-α) and 4 (DCLK-long-β) were generated
using SparksX Fold Recognition software [49]. Docking
analyses were carried out with PatchDock [50] and re-
sults were visualized with UCSF Chimera and LigPlot +
[51]. Model predictions were checked for reasonable
precision by repeating the modeling procedures using
SwissModel [52].Cell culture
AsPC-1, MiaPaCa-2, and SW1990 human pancreatic can-
cer cells, and HCT116, HT-29, and DLD-1 human colo-
rectal cancer cells, were obtained from ATCC and grown
in Dulbecco’s Modified Eagle’s Medium with 4.5 g/L glu-
cose and L-glutamine, without sodium pyruvate (Cellgro)
supplemented with 10% fetal bovine serum (Sigma) at 37°C
and 5% CO2.
Site-directed mutagenesis and lentiviral plasmid
construction
Human DCLK1 isoform short-α cDNA tagged with tur-
boGFP (tGFP) (Origene) was used to create a kinase-dead
mutant, in which the lysine at residue 419 was substituted
with an arginine by site-directed mutagenesis using the
QuickChange II mutagenesis kit (Agilent Technologies).
The mutant construct was confirmed by DNA sequencing.
Both wild-type DCLK1-tGFP and K419R-tGFP cDNAs
were then amplified and ligated into pCR8-GW-TopoD
(Invitrogen) following the manufacturer’s protocol. Wild-
type DCLK1-tGFP and K419R-tGFP cDNAs were then
transferred to pLenti CMV PURO DEST empty (gift from
Dr. Eric Campeau) using Clonase 2 (Invitrogen) following
the manufacturer’s recommendations.
Generation of lentiviral particles and cell lines
The expression plasmids constructed above were co-
transfected along with packaging plasmids pMD2.G
(Addgene), pMDL/RRE g/p (Addgene) and pRSV-Rev
(Addgene) into 293 T cells. DNA was transfected into
cells using the PEI transfection method with a PEI to
DNA ratio of 1:1. Supernatants were harvested 48 and
72 h post-transfection and cleared through a 0.45 μm fil-
ter. These viral supernatants were concentrated using
polyethylene glycol 8000 (Sigma-Aldrich) as previously
described [53] and cells were infected with concentrated
virus and selected with puromycin (Sigma-Aldrich) to
establish stable cell lines.
Cell proliferation assays
Cells (104 cells per well) were seeded into a 96-well tis-
sue culture plate in triplicate. The cells were cultured in
the presence of LRRK2-IN-1 with DMSO as a vehicle at
0, 0.31, 0.63, 1, 2, and 5, 10, and 20 μM. 48 h post treat-
ment, 10 μl of TACS MTT Reagent (RND Systems) was
added to each well and the cells were incubated at 37°C
until dark crystalline precipitate became visible in the
cells. 100 μl of 266 mM NH4OH in DMSO [54] was
then added to the wells and placed on a plate shaker at
low speed for 1 minute. After shaking, the plate was
allowed to incubate for 10 minutes protected from light
and the OD550 for each well was read using a microplate
reader. The results were averaged and calculated as a
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ard error of the mean.
Live-dead and Caspase 3/7 activity assays
AsPC-1 cells were seeded into a 96-well plate at 104 cells
per well and allowed to attach overnight at 37°C.
LRRK2-IN-1 was added to the wells at concentrations of
0 (DMSO), 0.3, 0.6, 1.25, 2.5, 5, 10, and 20 μM in duplicate
and incubated at 37°C for 24 h. Fluorescent Live/Dead
viability (Invitrogen) and luminescent CaspaseGlo® 3/7
activity (Promega) assays were performed according to
the manufacturer’s protocol.
Flow cytometry
To assess cell cycle status, AsPC-1 cells were treated
with LRRK2-IN-1 for 24 or 48 h, trypsinized, centrifuged
at 4°C, washed with Automacs rinsing solution (Milte-
nyi), and then fixed in 70% ethanol on ice for 30 minutes.
Following fixation the cells were washed with Automacs
rinsing solution and incubated with propidium iodide
(50 μg/ml) and treated with RNAse A. In another ex-
periment to analyze the cycling status of smaller subpop-
ulations of cells this process was repeated with longer
fixation (>2 h) and the addition of 0.1% Triton-X 100 for
permeabilization. Data was collected on FACS Calibur
and analyzed in ModFit LT.
Matrigel transwell invasion assays
Control or matrigel coated transwells (BD Biosciences)
were prepared by soaking in serum-free media for 2 h at
37°C in a 24-well plate. Subsequently, AsPC-1 cells
(5000/well) were seeded into each transwell in serum-
free media and treated with LRRK2-IN-1 or DMSO (ve-
hicle) in duplicate. Cell culture medium containing 10%
FBS was added to the bottom of each well as chemo-
attractant and the cells were incubated for 22 h. After-
wards, a cotton swab was used to scrape non-invasive/
migratory cells off the top of transwells and the remaining
cells were fixed with 100% methanol, stained with 1%
toluidine blue/1% borax, and allowed to dry. After drying,
the film from the transwell inserts was removed with a
scalpel blade and mounted on slides. For each sample 5
fields were counted at 10X magnification. Percent inva-
sion was calculated by dividing the number of invading
cells (matrigel-coated inserts) by the number of migrating
cells (control inserts) and multiplying by 100.
Colony formation assay
AsPC-1 cells (5000/well) overexpressing DCLK1, DCLK1-
K419R, or vector were seeded into 6 cm dishes in cell cul-
ture media containing 10% FBS and either DMSO or
LRRK2-IN-1 at 0.5 or 5 μM. The cells were allowed to
grow for 9 days and then washed with PBS, fixed with gla-
cial acetic acid/methanol solution (1:3), and washed withPBS again. Colonies were stained with 0.5% crystal violet
for 15 minutes and washed with tap water to remove ex-
cess stain. Colonies were then counted under a stereo-
microscope using a 1 cm2 grid. Four squares from four
quadrants were counted for each plate. The results were
normalized to DMSO for each cell line in order to obtain
the percent of colony formation. Stained colonies were
then imaged, thresholded in ImageJ, and highlighted for
visualization using the find edges ImageJ function.
Wound healing assay
105 AsPC-1 cells were seeded into 6-well plates and
allowed to grow to confluence. A sterile 200 μl pipette
tip was used to scratch the confluent layer, and detached
cells were removed with washing. For each plate 9 points
were selected and marked and baseline images were
taken at 4× magnification. Following baseline imaging
drug or vehicle was added to each well. Images were
again taken at 12, 24, 48, and 72 h. The migrating edges
were detected using the find edges function in ImageJ
and images were converted to 16-bit format and thre-
sholded. The empty region between migrating mono-
layer edges was selected and the area was measured
using the measure tool. These values were used to per-
form standard calculations and migration over time was
assessed by ANOVA.
Quantitative real-time RT-PCR
AsPC-1 cells (105/well) were seeded into 6-well plates in
triplicate in the presence of LRRK2-IN-1 and incubated
at 37°C for 8 h. The cells were lysed, and total RNA was
isolated using Tri Reagent (MRC) per the manufacturer’s
instructions. First strand cDNA synthesis was carried
out using SuperScript II Reverse Transcriptase and ran-
dom hexanucleotide primers (Invitrogen). The comple-
mentary DNA was subsequently used to perform RT-PCR
on an iCycler IQ5 Thermal Cycler (BioRad) using SYBR
Green (Molecular Probes) with gene-specific primers and
JumpStart™ Taq DNA polymerase (Sigma). The crossing
threshold value assessed was normalized to β-actin and
quantitative changes in mRNA were expressed as fold-
change relative to control ± SEM value. The Student’s
t-test was used to determine statistical significance. The
primer sequences for the genes analyzed are provided in
Additional file 1: Table S1.
Generation of phospho-DCLK1 antibody
A rabbit polyclonal antibody was commercially generated
(Abbomax) to target ser-30(β)/336(α), which has previously
been demonstrated to be phosphorylated, against a 15
amino acid peptide sequence similar to others previously
used to generate phospho-DCLK1 antibodies [46,55]. To
confirm specificity, ELISA was performed using phosphos-
pecific and non-phosphospecific peptide.
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Denatured proteins of cell lysates were subjected to
Western blot analysis. The concentration of total proteins
was determined by BCA protein assay (Pierce, Rockford,
IL). 40 μg of total proteins was separated on a 7.5%–15%
SDS polyacrylamide gel and transferred onto a PVDF
membrane. The membrane was blocked in 5% non-fat dry
milk for 1 h and probed overnight with primary antibody.
Subsequently the membrane was incubated with infrared
cw800-conjugated secondary antibody for 1 h at room
temperature. The proteins were detected using a LICOR
Odyssey Infrared Imager. Protein density quantification
was performed in Image Studio Lite (LICOR). The
antibodies used were α-DCLK1 (ABCAM, AB31704),
α-phosphoDCLK1, α-C-MYC (Santa Cruz, SC-40), α-
BCL2 (Santa Cruz, SC-492), and α-phosphohistone
H3 (EMD-Millipore 07–492).Immunofluorescence
Cells grown on glass coverslips and treated with DMSO
or LRRK2-IN-1 were rinsed with PBS, fixed in formalin,
rinsed again with PBS, and permeabilized with 0.1%
Triton-X. Following permeabilization cells were incu-
bated at 4°C overnight with α-phosphohistone H3 di-
luted 1:10000 in 0.01% Triton-X containing 1% BSA.
After incubation, cells were washed with PBS, and sec-
ondary antibody (Alexa-Fluor 547) diluted 1:2000 in
PBS was added and allowed to incubate for 30 minutes
at room temperature. After washing with PBS the cover-
slips were counterstained with Hoechst 33342, rinsed
with PBS and distilled water, mounted on slides using
Prolong gold antifade reagent (Invitrogen), and imaged
with a Nikon Eclipse Ti microscope.Xenograft tumor study
AsPC-1 cells (5×105) were injected subcutaneously into
the flanks of athymic nude mice and allowed to grow
until the tumor reached an average volume of 100 mm3.
LRRK2-IN-1 was solubilized in 20% Captisol® and the
xenografts were injected peritumorally with either 20%
Captisol (vehicle) or LRRK2-IN-1 (100 mg/kg). Injec-
tions were performed on Monday, Wednesday, and Fri-
day for 4 weeks (a total of 12 injections). Horizontal and
vertical tumor diameter was measured on each injection
date with calipers and tumor volume was calculated
using the formula: tumor volume = 0.5 × length × width2.
At the end of the injection period mice were killed by
CO2 asphyxiation and tumors were excised, weighed,
and measured. All animal experiments were performed
in accordance with standards set forth by the University
of Oklahoma Health Sciences Center’s Institutional Animal
Care and Use Committee.Analysis of TCGA and NCBI GEO datasets
To perform The Cancer Genome Atlas (TCGA) Colon
Adenocarcinoma (COAD) dataset analysis, isoform spe-
cific RNA-seq results for all stages of colon adenocarcin-
oma were downloaded from the TCGA open-access
server. A workflow in Knime (version 2.8.1) was used to
identify and aggregate transcript data. NCBI gene expres-
sion omnibus (GEO) datasets were downloaded using
NCBI’s built in GEO2R analysis tool.
Statistical analysis
All statistical analyses were performed using Graphpad
Prism 6.0 and Microsoft Excel. One-way ANOVA and
the Student’s T-test were used to determine statistical
significance unless otherwise noted. For all analyses
p < 0.05 was considered to be statistically significant.
Additional file
Additional file 1: Table S1. Primers sequence for genes analyzed by
real-time RT-PCR. Figure S1. Cladogram of proteins closely related to
DCLK1 as determined by ClustalΩ using the human kinome as input.
Highlighting denotes solved structures (A) Anti- proliferative effect of
LRRK2-IN-1 on colon and pancreatic cancer cell lines 48 h post-treatment
(B). Figure S2. Two-dimensional plot of LRRK2-IN-1 and interacting
residues as plotted by LigPlot and color-coded to agree with Figure 1E Red
rays denote hydrophobic interactions and the green dashed line denotes
2.63A length hydrogen bonding between the ligand and Aspartate 226.
Residue labeling agrees with the SwissProt entry for DCLK1 isoform 4 (A).
Fluorescent images of cells stained with Calcein-AM (Live/Green) and Eth-D
(Dead/Red) following LRRK2-IN-1 treatment (B). NCBI Geo data of DCLK1
gene expression in various pancreatic cancer cell lines compared to HPDE
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NCI-60 cell panel (GDS 1761) (C) Exponential plots demonstrating strong
associations between cell death and caspase activity and percentage of G2/M
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